Zhiran Medical has secured another 300 million yuan in A+ round financing within six months, accelerating the clinical implementation of invasive brain-machine interfaces

Recently, domestic invasive brain-computer interface company ZhiRan Medical completed a 300 million yuan A+ round of financing, led by Zhongke Chuangxing, with collective follow-on investment from existing shareholders. The funds will be used to advance large-scale clinical trials and the iteration of high-throughput flexible electrode products. The company has broken through core technologies such as stretchable flexible electrodes and domestically produced neural chips, and has completed the first clinical implantation in the country with over 100 channels. It plans to initiate large-scale registered clinical trials in 2026, promoting the transformation of invasive brain-computer interfaces from technology to application